Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... September 30, 2014. "During the quarter, ... beginning of 2014 by securing a partner to accelerate the ... market into countries where we do not have a commercial ... this partnership will maximize the value of PIXUVRI for CTI ...
(Date:10/30/2014)... 2014 Today Eli Lilly and Company (NYSE: ... technology transfer program to increase the global supply of ... effort included Lilly donating manufacturing technology and know-how for ... , India , ... – all MDR-TB ,hot spots., It also served ...
Breaking Medicine Technology:Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
... 2007 - Genmab A/S (CSE: GEN),announced today that ... (HuMax-CD20™) in patients with rheumatoid,arthritis (RA) have been ... Congress of Rheumatology (EULAR). The oral,presentation, which will ... II study with ofatumumab, along with data,from the ...
Cached Medicine Technology:Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... a common plastics, chemical during pregnancy may have effects on ... Researchers found that baby boys born to moms with greater ... shorter anogenital distance -- the space between the genitals and ... considered a marker of exposure to androgens ("male" hormones) during ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... opinions about the Affordable Care Act are sharply divided ... voters are strongly in favor of the Affordable Care ... Democrats want the next Congress to move ahead with ... current law, while 44 percent want to expand the ... want the law repealed, and 27 percent want it ...
(Date:10/30/2014)... respects the fact that a patient,s body is ... Over a third of cancer patients experience psychosocial ... conditions. And, increasingly, care providers are exploring phone- ... mental health challenges. A University of Colorado Cancer ... Psycho-Oncology asks an important question: after decades ...
Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2
... day to analysis and expert thought, they may be able ... of the precise type of brain tumour they face. Now ... technique that can give a preliminary analysis of the precise ... the brain and nervous system and they account for 20% ...
... Rosemont, Ill. - June 17, 2008- Current protein recommendations ... newer research indicates that many adults may benefit from ... presented in a supplement in the May issue of ... describing the conclusions of a Protein Summit ...
... on invasion and migration in colorectal cancer cell line. This ... performed by a team led by Professor Ji-Kun Li from ... article to be published on April 21, 2008 in the ... of the main causes of cancer-related death in the world. ...
... 17 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... the current issue of EuroIntervention was recognized by the,journal,s ... submitted to the,journal this past winter. Lutz Buellesfeld, M.D., ... of the study,s investigators, received,an award in conjunction with ...
... Ala., June 17 Emageon Inc.,(Nasdaq: EMAG ... for hospitals, healthcare networks and imaging facilities announced,today ... present at the,Jefferies 2nd Annual Healthcare Conference on ... 24th at 8:30 AM ET. The presentation will ...
... 17 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... Skin,Rejuvenation(TM) a new Iceland Health-branded product. Skin Rejuvenation ... capsule form,designed to reduce, at the cellular level, ...
Cached Medicine News:Health News:Wavelets crunch through doctors' day long struggle to diagnose brain tumors 2Health News:Is it time to revisit the current protein recommendations? 2Health News:Is it time to revisit the current protein recommendations? 3Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 2Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 3Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 2Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 3
Adhesive tape sheets for sealing multiwell plates and blocks;...
Microwell Plate Accessories...
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Medicine Products: